BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 14640701)

  • 1. Degradation of beta-amyloid by proteolytic antibody light chains.
    Rangan SK; Liu R; Brune D; Planque S; Paul S; Sierks MR
    Biochemistry; 2003 Dec; 42(48):14328-34. PubMed ID: 14640701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity.
    Liu R; McAllister C; Lyubchenko Y; Sierks MR
    Biochemistry; 2004 Aug; 43(31):9999-10007. PubMed ID: 15287727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments.
    Kasturirangan S; Brune D; Sierks M
    Biotechnol Prog; 2009; 25(4):1054-63. PubMed ID: 19572401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway.
    Hook VY; Reisine TD
    J Neurosci Res; 2003 Nov; 74(3):393-405. PubMed ID: 14598316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity.
    Kasturirangan S; Boddapati S; Sierks MR
    Biochemistry; 2010 Jun; 49(21):4501-8. PubMed ID: 20429609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response to fibrillar beta-amyloid peptide.
    Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
    Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.
    Vingtdeux V; Hamdane M; Gompel M; Bégard S; Drobecq H; Ghestem A; Grosjean ME; Kostanjevecki V; Grognet P; Vanmechelen E; Buée L; Delacourte A; Sergeant N
    Neurobiol Dis; 2005 Nov; 20(2):625-37. PubMed ID: 15936948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of beta-secretase-like activity using a mass spectrometry-based assay system.
    Grüninger-Leitch F; Berndt P; Langen H; Nelboeck P; Döbeli H
    Nat Biotechnol; 2000 Jan; 18(1):66-70. PubMed ID: 10625394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
    Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
    Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
    Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
    J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.
    McCarty MF
    Med Hypotheses; 2006; 67(4):682-97. PubMed ID: 16828233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production.
    Zhou S; Zhou H; Walian PJ; Jap BK
    Proc Natl Acad Sci U S A; 2005 May; 102(21):7499-504. PubMed ID: 15890777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42.
    Funamoto S; Morishima-Kawashima M; Tanimura Y; Hirotani N; Saido TC; Ihara Y
    Biochemistry; 2004 Oct; 43(42):13532-40. PubMed ID: 15491160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease.
    Johnston JA; Liu WW; Todd SA; Coulson DT; Murphy S; Irvine GB; Passmore AP
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1096-100. PubMed ID: 16246054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
    Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
    Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.